July notches seven PBS listings

Posted 2 July 2025 AM

There have been seven additions to the PBS this month, including two new medicines, a biosimilar, and four expansions for big brands.

Among the newbies is Servier’s first-in-class IDH1 inhibitor Tibsovo, which has been subsidised for the treatment of adults with locally advanced or metastatic cholangiocarcinoma who have previously progressed on chemotherapy and have a confirmed IDH1 mutation. The company won a recommendation for the drug at the November 2024 meeting via the early re-entry pathway.

To see the whole article, please login